SAB Biotherapeutics Stock (NASDAQ: SABS) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 81.000 / 14.203K |
Day Range | - - - |
52 Wk Range | 4.000 - 11.900 |
Market Cap | $46.127M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 57 |
Short Interest | 0.41% |
Days to Cover | 2.56 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of SAB Biotherapeutics (NASDAQ: SABS) through any online brokerage.
Other companies in SAB Biotherapeutics’s space includes: NKGen Biotech (NASDAQ:NKGN), Fortress Biotech (NASDAQ:FBIO), Estrella Immunopharma (NASDAQ:ESLA), Acurx Pharmaceuticals (NASDAQ:ACXP) and OncoCyte (NASDAQ:OCX).
The latest price target for SAB Biotherapeutics (NASDAQ: SABS) was reported by HC Wainwright & Co. on Tuesday, April 16, 2024. The analyst firm set a price target for 6.00 expecting SABS to rise to within 12 months (a possible 20.00% upside). 13 analyst firms have reported ratings in the last year.
The stock price for SAB Biotherapeutics (NASDAQ: SABS) is $5 last updated April 16, 2024 at 7:16 AM EDT.
There are no upcoming dividends for SAB Biotherapeutics.
SAB Biotherapeutics’s Q1 earnings are confirmed for Tuesday, May 14, 2024.
There is no upcoming split for SAB Biotherapeutics.
SAB Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.